The president wants to enforce involuntary commitment laws for severe drug use. But rehab is expensive, without enough beds for those who seek it. By Jan Hoffman The sight is increasingly common: ...
Gilead Sciences Inc (NASDAQ:GILD) is facing mounting pressure to price its long-acting HIV prevention drug, lenacapavir, affordably as it prepares for U.S. regulatory approval on June 19. In December ...
Thousands of heart attacks could be prevented if the NHS prescribed a "low-cost" drug combination, according to new research. A study conducted by an international team of scientists suggests that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback